| pubmed-article:21320733 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:21320733 | lifeskim:mentions | umls-concept:C0030705 | lld:lifeskim |
| pubmed-article:21320733 | lifeskim:mentions | umls-concept:C0229671 | lld:lifeskim |
| pubmed-article:21320733 | lifeskim:mentions | umls-concept:C0442874 | lld:lifeskim |
| pubmed-article:21320733 | lifeskim:mentions | umls-concept:C0441889 | lld:lifeskim |
| pubmed-article:21320733 | lifeskim:mentions | umls-concept:C0067385 | lld:lifeskim |
| pubmed-article:21320733 | pubmed:issue | 2 | lld:pubmed |
| pubmed-article:21320733 | pubmed:dateCreated | 2011-5-16 | lld:pubmed |
| pubmed-article:21320733 | pubmed:abstractText | The goal of our study was to evaluate the role of asymmetric dimethylarginine (ADMA) in patients with diabetic neuropathy. | lld:pubmed |
| pubmed-article:21320733 | pubmed:language | eng | lld:pubmed |
| pubmed-article:21320733 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21320733 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:21320733 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21320733 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21320733 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:21320733 | pubmed:month | May | lld:pubmed |
| pubmed-article:21320733 | pubmed:issn | 1872-8227 | lld:pubmed |
| pubmed-article:21320733 | pubmed:author | pubmed-author:Saraço?luMehm... | lld:pubmed |
| pubmed-article:21320733 | pubmed:author | pubmed-author:SenolMehmet... | lld:pubmed |
| pubmed-article:21320733 | pubmed:author | pubmed-author:Ya?arHalitH | lld:pubmed |
| pubmed-article:21320733 | pubmed:author | pubmed-author:KendirliTanse... | lld:pubmed |
| pubmed-article:21320733 | pubmed:author | pubmed-author:ÖnemYalç?nY | lld:pubmed |
| pubmed-article:21320733 | pubmed:author | pubmed-author:Özda?FatihF | lld:pubmed |
| pubmed-article:21320733 | pubmed:copyrightInfo | Copyright © 2011 Elsevier Ireland Ltd. All rights reserved. | lld:pubmed |
| pubmed-article:21320733 | pubmed:issnType | Electronic | lld:pubmed |
| pubmed-article:21320733 | pubmed:volume | 92 | lld:pubmed |
| pubmed-article:21320733 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:21320733 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:21320733 | pubmed:pagination | 223-7 | lld:pubmed |
| pubmed-article:21320733 | pubmed:meshHeading | pubmed-meshheading:21320733... | lld:pubmed |
| pubmed-article:21320733 | pubmed:meshHeading | pubmed-meshheading:21320733... | lld:pubmed |
| pubmed-article:21320733 | pubmed:meshHeading | pubmed-meshheading:21320733... | lld:pubmed |
| pubmed-article:21320733 | pubmed:meshHeading | pubmed-meshheading:21320733... | lld:pubmed |
| pubmed-article:21320733 | pubmed:meshHeading | pubmed-meshheading:21320733... | lld:pubmed |
| pubmed-article:21320733 | pubmed:meshHeading | pubmed-meshheading:21320733... | lld:pubmed |
| pubmed-article:21320733 | pubmed:meshHeading | pubmed-meshheading:21320733... | lld:pubmed |
| pubmed-article:21320733 | pubmed:meshHeading | pubmed-meshheading:21320733... | lld:pubmed |
| pubmed-article:21320733 | pubmed:meshHeading | pubmed-meshheading:21320733... | lld:pubmed |
| pubmed-article:21320733 | pubmed:meshHeading | pubmed-meshheading:21320733... | lld:pubmed |
| pubmed-article:21320733 | pubmed:year | 2011 | lld:pubmed |
| pubmed-article:21320733 | pubmed:articleTitle | Serum asymmetric dimethylarginine levels in diabetic patients with neuropathy. | lld:pubmed |
| pubmed-article:21320733 | pubmed:affiliation | GATA Haydarpa?a Training Hospital, Department of Neurology, Istanbul, Turkey. | lld:pubmed |
| pubmed-article:21320733 | pubmed:publicationType | Journal Article | lld:pubmed |
